Gesellschaftsrecht / M&A

Kapitalmarkt

Finanzierungen und Anlageprodukte

Steuern

Arbeitsrecht und Vergütung für Führungskräfte

Dufry_bw

On February 3, 2023, Dufry AG (SIX: DUFN) announced that it successfully closed the transfer of the 50.3% stake in Autogrill S.p.A (XMIL: AGL) held by Edizione S.p.A (through a wholly owned subsidiary) to Dufry.
Dufry will launch a mandatory public exchange offer for the remaining Autogrill shares (excluding treasury shares) at the same terms as Edizione and with a cash alternative of EUR 6.33 per Autogrill share.
Dufry expects to complete the full transaction including the mandatory exchange offer settlement by the end of Q2 2023.
Homburger acts as transaction counsel to Dufry. The Homburger team comprises Andreas Müller, Frank Gerhard, Oliver Kneubühl and Carlo Sulser (all Corporate / M&amp;A; Capital Markets), Jürg Frick, Eduard De Zordi, Alexander Wherlock and Nathalie Scherrer (all Financing and Investment Products / Capital Markets), Dieter Grünblatt and Reto Heuberger (both Tax), and Nicole Hilpert and Angela Casey (Employment and Executive Compensation).

Homburger advises Dufry on the successful closing of its strategic combination with Autogrill

IP / IT

Datenschutz

HIG Capital

On November 3, 2022, H.I.G. Capital, a leading global investment firm with USD 52 bn of equity capital under management, announced that one of its affiliates has completed the acquisition of Celerion Holdings Inc., a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.
The Homburger team comprised partner Andreas Müller, lead associate Sarah Chevalley, associate Oliver Kneubühl and junior associate Michele Fazari (all Corporate / M&amp;A), associates Joel Fink (IP / IT) and Kirsten Wesiak-Schmidt (Data Protection).

Homburger advised H.I.G. Capital on its acquisition of Celerion

Vectivio

On October 13, 2022, VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the release of its interim data from the first five of nine patients in its ongoing Phase 2 STARS Nutrition clinical trial, the pricing of a USD 125 m underwritten offering of ordinary shares, and an amendment to its financing agreement with Kreos Capital VI (UK) Limited, including the right to receive additional warrants under certain conditions.
The underwritten offering consists of 16,700,000 ordinary shares at an offering price of USD 7.50 per share. Investors include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion&#8217;s Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors.
The Homburger team includes partner Andreas Müller, associates Margrit Marti and Oliver Kneubühl, and junior associate Julien Di Sabato (all Capital Markets; Corporate / M&amp;A), partner Jürg Frick, associates Simone Gloor and Stefan Bindschedler, and junior associate Thibault Sieber (all Financing and Investment Products), partner Stefan Oesterhelt and associate Kevin Müller (both Tax), and partner Luca Dal Molin (IP / IT).

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Oliver
Kneubühl

Homburger advises Dufry on the successful closing of its strategic combination with Autogrill

Homburger advised H.I.G. Capital on its acquisition of Celerion

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Karriere

Sprachen

Teams

OliverKneubühl

Homburger advises Dufry on the successful closing of its strategic combination with Autogrill

Homburger advised H.I.G. Capital on its acquisition of Celerion

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Karriere

Sprachen

Teams

Oliver
Kneubühl